Data Presented at the ESMO 2017 Annual Meeting showed that Abiraterone Acetate (Zytiga) plus prednisone provides benefits in patient reported outcomes in hormone-sensitive and castration-resistant prostate cancer that has remained in the prostate gland.
Prior data from the LATITUDE Trial has shown that Zytiga and prednisone along with hormone therapy (ADT) provide newly diagnosed men with aggressive prostate cancer who are still castrate sensitive (still responding to ADT) with a better overall survival benefit compared to what had been the standard of care, ADT alone.
Additional data presented at the ESMO meeting that came from the LATITUDE trial, showed that treatment with Zytiga plus prednisone, in combination with hormone therapy (ADT), provided clinically meaningful and statistically significant improvements in many patients reported outcomes (PRO) in men with newly diagnosed, high-risk, metastatic hormone-sensitive prostate cancer compared to the standard of care, only ADT.
The data showed that treatment with Zytiga plus prednisone, in combination with ADT, significantly delayed time to pain progression; pain interference; worst fatigue and fatigue interference compared to ADT plus placebos.
The additional findings also show significant improvement in health-related quality of life (HRQoL), which includes several measures such as physical and emotional well being, demonstrating a reduction in risk of HRQoL degradation compared to ADT plus placebos.
The bottom line we learn from this additional data is that for men with newly diagnosed castrate sensitive aggressive prostate cancer the combination of Zytiga plus prednisone with ADT is superior to ADT alone both for its survival advantage as well as other important quality of life issues.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer a rare cancer.
